Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Tee, Augustine K H ^a   Koh, M S ^b   Gibson, P G ^b   Lasserson, T J ^b   Wilson, A J ^b   Irving, L B ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b NONE

Author keywords

Adrenergic beta agonists *therapeutic use ; Albuterol *analogs derivatives; therapeutic use ; Asthma drug therapy; *prevention control ; Bronchodilator agents *therapeutic use ; Delayed action preparations

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BITOLTEROL; FORMOTEROL; KETOTIFEN; LONG ACTING DRUG; SALMETEROL; THEOPHYLLINE;

ASTHMA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; EAR NOSE THROAT DISEASE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAINTENANCE THERAPY; PEAK EXPIRATORY FLOW; RESPIRATORY TRACT DISEASE; REVIEW; SLOW RELEASE FORMULATION; TACHYCARDIA; THROAT DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 42949167313     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001281.pub2     Document Type: Review

References (51)

1. Filiz 2002 {published data only} Filiz A, Bozkurt N. Addition of Salmeterol or Theophylline to an inhaled Corticosteroid Regimen in Patients with Severe Asthma. Turkish Respiratory Journal 2002;3(3):98-101.
2. Fjellbirkeland 1994 {published data only} Fjellbirkeland L, Gulsvik A, Palmer JBD. The efficacy and tolerability of inhaled salmeterol and individual dose-titrated, sustained-release theophylline in patients with revesible airways disease. Respiratory Medicine 1994;88(8):599- 607.
3. Malolepszy 2002 {published data only} *Malolepszy J. Efficacy and tolerability of oral theophylline slow release versus inhalative formoterol in moderate asthma poorly controlled on low dose steroids [Wirksamkeit und Vertraglichkeit einer oralen Theophyllin -Retardzubereitung im Vergleich zu inhaliertem Formoterol bei mittelschwerem, mit niedrig dosierten Steroiden unzureichend kontrolliertem Asthma]. Atemwegs- und Lungenkrankheiten 2002;28:78-87.
4. Muir 1992 {published data only} *Muir JF, Bertin D, French Multicentre Study group. Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial. European Respiratory Journal 1992;5(10):1197-200.
5. Muir JF, Georges D. Effect of salmeterol in nocturnal asthma: comparative study with combination theophylline and ketotifen [Apport du salmétérol dans l'asthme nocturne: étude comparative à l'association théophlline LA-kétotifène]. Revue des Maladies Respiratoires 1992;9:23-26.
6. Nutini 1998 {published data only} Nutini S, Martini T, Righi R. Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline. Respiratory Medicine 1998;92(4):683-90.
7. Paggiaro 1996 {published data only} Paggiaro PL, Giannini D, Di Franco A, Testi R. Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Respiratory Journal 1996;9(8):1689-95.
8. Pastorello 1998 {published data only} Pastorello AE, Mauro M, Incorvaia C. Comparison of efficacy and safety of inhaled salmeterol and slow-release oral theophylline in patients with moderate/severe asthma [Confronto di efficacia e tollerabilita tra salmeterolo per via inalatoria e teofillina orale e lento rilascio in pazienti affetti da asma di grado medio/grave]. L'internista 1998;6:101-7.
9. Pollard 1997 {published data only} Pollard SJ, Sheldon LS, Yancey SW, Cox FM, Emmett A. Salmeterol versus theophylline in the treatment of asthma. Annals of Allergy, Asthma & Immunology 1997;78(5):457- 64.
10. Selby 1997 {published data only} Selby C, Engleman HM, Fitzpatrick MF, Sime PM, Mackay TW, Douglas NJ. Inhaled salmeterol or oral theophylline in nocturnal asthma?. American Journal of Respiratory & Critical Care Medicine 1997;155(1):104-8.
11. Ukena 1997 {published data only} Ukena D, Koper I, Braun H, Leutz M, Schlimmer P, Sybrecht GW. Treatment of Nocturnal Asthma: Salmeterol Versus Once Per Evening Dose of Sustained Release Theophylline. Comparison of Efficacy and Tolerability [Therapie des nachtlichen Asthmas: Salmeterol versus abendliche Einnahme von retardiertem Theophyllin - Vergleich der Wirksamkeit und der Vertraglichkeit]. Pneumologie 1997;51:317-23.
12. Wiegand 1999 {published data only} Wiegand L, Mende CN, Zaidel G, Zwillich CW, Petrocella VJ, Yancey SW, et al.Salmeterol vs Theophylline: Sleep and Efficacy Outcomes in Patients With Nocturnal Asthma. Chest 1999;115(6):1525-32.
13. Yurdakul 2002 {published data only} Yurdakul AS, Calisir HC, Tuncan B, Ogretensoy M. Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. Respiratory Medicine 2002;96(5):322-9.
14. Zwillich 1989 {published data only} Zwillich CW, Neagley SR, Cicutto L, White DP, Martin RJ. Nocturnal asthma therapy: Inhaled bitolterol versus sustained-release theophylline. American Review of Respiratory Disease 1989;139(2):470-4.
15. Avidsson 1991 Avidsson P, Larsson S, Lofdahl CG, Melander B, Svedmyr N, Wahlander L. Inhlaed formoterol during one year in asthma: a comparison with salbutamol. European Respiratory Journal 1991;4(10):1168-73.
16. Barnes 1992 Barnes PJ. New drugs for asthma. European Respiratory Journal 1992;5(9):1126-36.
17. Brogden 1991 Brogden RN, Faulds D. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991;42(5):895-912.
18. Brogden 1992 Brogden RN, Faulds D. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Allergologia et Immunopathologia 1992;20(2):72-84.
19. Cheung 1998 Cheung D, Wever AM, de GOEIJ JA, de GRAAF CS, Steen H, Sterk PJ. [Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in asthmatics in vivo]. American Journal of Respiratory & Critical Care Medicine 1998;158(3):792-6.
20. Davies 2000 Davies B, Brooks G, Devoy M. [The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies]. Respiratory Medicine 1998;92(2):256-63.
21. Donohue 2001 Donohue JF, Ohar JA. [New combination therapies for asthma]. Current Opinion in Pulmonary Medicine 2001;7(2):62-8.
22. Dutta 2002 Dutta EJ, Li JTC. [Beta- agonists]. Medical Clinics of North America 2002;86(5):991-1008.
23. Eda 1993 Eda R, Sugiyama H, Hopp RJ, Okada C, Bewtra AK, Townley RG. Inhibitory effects of formoterol on platlet-activating factor induced eosinophil chemotaxis and degranulation. International Archives of Allergy & Immunology 1993;102(4):391-8.
24. Faulds 1991 Faulds D, Hollingshead LM, Goa KL. Formoterol. A review of tis pharmacological properties and therapeutic potential in reversible obstrcutive airways disease. Drugs 1991;42(1):115-37.
25. Gokhale 2002 Gokhale AB, Saraf MN. [Recent developments in asthma therapy]. Indian Drugs 2002;39(3):121-32.
26. Hancox 2001 Hancox RJ, Taylor DR. Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids. Biodrugs 2001;15(1):11-24.
27. Holimon 2001 Holimon TD, Chafin CC, Self TH. Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists. Drugs 2001;61(3):391-418.
28. Hunt 2002 Hunt LW. The critical components of asthma management. Drug Benefit Trends 2002;14(1):21-22, 24-25, 28, 30.
29. Kleerup 1997 Kleerup EC. Bronchodilators: new drugs and controversies. Current Opinion in Pulmonary Medicine 1997;3(1):17- 22.
30. Lockey 1999 Lockey RF, Dubuske LM, Friedman B, Petrocella V, Cox F, Rickard K. Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes. Chest 1999;115(3):666-73.
31. Lotvall 1992 Lotvall J, Lunde H, Ulman A, Tornquist H, Svedmyr N. Twelve months, treatment with inhlaed salmeterol in asthmatic patients. Effects on beta 2-receptor function and inflammatory cells. Allergy 1992;47(5):477-83.
32. Manchee 1996 Manchee GR, Eddershaw PJ, Ranshaw LE, Herriot D, Park GR, Bayliss MK, et al.The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol inhuman liver microsomes in catalyzed by CYP3A. Drug Metabolism and Disposition 1996;24(5):55-9.
33. Meier 1997 Meier CR, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax 1997;52(7):612-7.
34. Midgren 1992 Midgren B, Melander B, Persson G. Formoterol, a new long-acting beta2 agonist, inhaled twice daily, in stable asthmatic subjects. Chest 1992;101(4):1019-22.
35. Morice 1999 Morice AH, Taylor ME. A randomised trial of the initiation of asthma treatment. Asthma in General Practice 1999;7(1):7-9.
36. Nelson 1996 Neslon HS. New developments in bronchodilator therapy. Current Opinion in Pulmonary Medicine 1996;2(1):35-9.
37. Nightingale 1995 Nightingale CH. Cost comparison of beta2 agonist bronchodilatros used in the treatment of asthma. Pharmacotherapy 1995;15(5):677-81.
38. Paciorek 1991 Paciorek PM, Burden DT, Gater PR, Hawthorne YM, Spence AM, Taylor JC, et al.Inhibition by Ro 31-6930 of agonist and allergen induced bronchoconstriction in anaesthetised guinea-pigs and cats. Pulmonary Pharmacology 1991;4(4):225-32.
39. Rossi 2002 Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, et al. [Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral, sustained-release theophylline in the treatment of COPD]. Chest 2002;121(4):1058-69.
40. Skloot 2002 Skloot GS. [Nocturnal asthma: mechanisms and management]. Mount Sinai Journal of Medicine 2002;69(3):140-7.
41. Taburet 1994 Taburet AM, Schmit B. Pharmacokinetic optimisation of asthma treatment. Clinical Pharmacokinetics 1994;26(5):396-418.
42. Taccola 1999 Taccola M, Bancalari L, Ghignoni G, Paggiaro PL. [Salmeterol versus slow release theophylline]. Monaldi Archive of Chest Disease 1999;54(4):302-6.
43. Thomson 1998 Thomson NC. Asthma therapy : theophylline. Canadian Respiratory Journal 1998;5(Suppl A):60-3.
44. Tomac 1996 Tomac N, Tuncer A, Saraclar Y, Adalioglu G. Efficacy of salmeterol in the treatment of childhood asthma. Acta Paediatrica Japonica 1996;38(5):489-94.
45. Vatrella 2005 Vatrella A, Ponticiello A, Plaia G, Parrella R, Cazzola M. Bronchodilating effects of salmeterol, theophylline and their combination in patients with moderate to severe asthma. Pulmonary Pharmacology & Therapeutics 2005;18(2):89-92.
46. Weinstein 1997 Weinstein S, Chervinsky P, Pollard SJ, Bronsky EA, Nathan RA, Prenner B, et al.A one-week dose-ranging study of inhaled salmeterol in children with asthma. Journal of Asthma 1997;34(1):43-52.
47. Davis 1997 Davis R, Noble S. Management of Asthma: Defining the Role of Salmeterol. Auckland, New Zealand: Adis International Limited, 1997.
48. Kaliner 1991 Kaliner MA, Barnes PJ, Persson CGA (Editors). Asthma: Its Pathology and Treatment. New York: Marcel Dekker, Inc, 1991.
49. Salpeter 2006 Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Annals of Internal Medicine 2006;144(12):904-912.
50. Shah 2003 Shah L, Wilson AJ, Gibson PG, Coughlan J. Long-acting beta2-agonists versus theophylline for maintanence treatment of asthma (Cochrane Review). Cochrane Database of Systematic Reviews 2003, Issue 3.
51. Wilson 2000 Wilson AJ, Gibson PG, Coughlan J. Long acting beta-agonists versus theophylline for maintenance treatment of asthma (Cochrane Review). Cochrane Database of Systematic Reviews 2000, Issue 2.